Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05256927 · ClinicalTrials.gov registry record
Is Milk Associated with Glycemia in the NICU
A clinical trial, sponsored by University of Rochester.
- Completed
- Registry status
- 124
- Enrollment target
NCT05256927: Completed study, sponsored by University of Rochester.
NCT05256927 is a clinical trial that has completed, run by University of Rochester. The registered enrollment target is 124 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05256927 has completed, sponsored by University of Rochester.
- COMPLETED
- Registry status
- 124 participants
- Enrollment target
Study Summary
The purpose of this study is to determine if concentrations of hormones in prepared human milk (HM) feeds are associated with metabolic disturbances in the recipient premature infant. To do so, prospectively 100 infants receiving HM-derived fortifiers as part of clinical care will be studied, saving aliquots of daily prepared feeds until any fortification ceases.
Primary Outcome
We will measure final insulin concentrations in enteral feed preparations that contain some portion of human milk.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 124 participants |
| Start Date | 2022-02-16 |
| Est. Completion | 2024-03-10 |
What the finished NCT05256927 record still lists
NCT05256927 is an observational study that tracks outcomes without assigning an intervention. The registered 124 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 0 interventions.
NCT05256927 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05256927 about?
NCT05256927 is a clinical study titled "Is Milk Associated with Glycemia in the NICU". The purpose of this study is to determine if concentrations of hormones in prepared human milk (HM) feeds are associated with metabolic disturbances in the recipient premature infant. To do so, prospectively 100 infants receiving HM-derived fortifiers as part of clinical care will be studied, saving...
What is the current status of trial NCT05256927?
This trial is currently completed. The enrollment target is 124 participants. The study started on 2022-02-16. Estimated completion is 2024-03-10.
Who is sponsoring clinical trial NCT05256927?
This trial is sponsored by University of Rochester, which has 636 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02523014 · 124 participants · Phase 2
Vismodegib, FAK Inhibitor GSK2256098, Capivasertib, and Abemaciclib in Treating Patients With Progressive Meningiomas
- NCT02670707 · 124 participants · Phase 3
Vinblastine/Prednisone Versus Single Therapy With Cytarabine for Langerhans Cell Histiocytosis (LCH)
- NCT02830724 · 124 participants · Phase 1
Administering Peripheral Blood Lymphocytes Transduced With a CD70-Binding Chimeric Antigen Receptor to People With CD70 Expressing Cancers
- NCT04748809 · 124 participants · NA
Effect of Anti-inflammatory Diet in Rheumatoid Arthritis
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI